Delray Beach, Fla. – – October 07, 2026 -- The global Active Pharmaceutical Ingredients (API) market will grow from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, a 6.0% compound annual growth rate, according to new data from MarketsandMarkets.
North America commands 43.1% of global API sales as domestic manufacturing investment accelerates
North America held the largest regional share of the API market in 2025 at 43.1%, driven by established pharmaceutical R&D infrastructure and rising investment in domestic production capacity. The US leads regional output in high-value and complex API development, supported by a dense base of pharmaceutical companies, contract manufacturing organizations, and specialized API producers.
Synthetic APIs and prescription drugs dominate segment demand
By synthesis route, synthetic APIs captured 78.6% of market share in 2025, reflecting entrenched manufacturing infrastructure for small-molecule drug production. Prescription drugs accounted for 89.9% of API demand the same year, tied to rising treatment needs in oncology, diabetes, and cardiovascular disease. Pharmaceutical companies represented the largest end-user category at 45.5% share, as drug developers scale production of innovative and complex therapies.
AbbVie and Cambrex commit $315 million combined to expand US API capacity
AbbVie announced a USD 195 million investment in August 2025 to expand API manufacturing at its North Chicago facility, targeting neuroscience, immunology, and oncology pipelines. Cambrex followed in October 2025 with a USD 120 million investment to boost API capacity and peptide manufacturing in the US. Both moves align with broader supply-chain reshoring efforts and government incentives aimed at securing domestic production of critical drug substances.
Revenue mix shifts toward high-potency APIs and peptides as fragmentation persists
Market revenue is migrating from commoditized, high-volume APIs toward higher-value categories including high-potency APIs, peptide APIs, and specialty small molecules. The top five players—Pfizer, Divi's Laboratories, Asymchem, Cipla, and Evonik—collectively hold just 2.8% to 3.7% of global market share, underscoring a fragmented competitive field of global and regional manufacturers, CDMOs, and captive pharmaceutical producers. The US FDA is actively promoting continuous manufacturing, distributed production, and AI-driven process controls through its advanced manufacturing programs, pushing API producers toward modular, high-containment facilities capable of handling complex and highly potent compounds.